» Articles » PMID: 37424799

Visualized Machine Learning Models Combined with Propensity Score Matching Analysis in Single PR-positive Breast Cancer Prognosis: a Multicenter Population-based Study

Overview
Journal Am J Cancer Res
Specialty Oncology
Date 2023 Jul 10
PMID 37424799
Authors
Affiliations
Soon will be listed here.
Abstract

The characteristics of single PR-positive (ER-PR+, sPR+) breast cancer (BC) and its prognosis are not well elucidated due to its rarity and conflicting evidence. There is a lack of an accurate and efficient model for predicting survival, thereby rendering treatment challenging for clinicians. Whether endocrine therapy should be intensified in sPR+ BC patients was another controversial clinical topic. We constructed and cross-validated XGBoost models that showed high precision and accuracy in predicting the survival of patients with sPR+ BC cases (1-year: AUC=0.904; 3-year: AUC=0.847; 5-year: AUC=0.824). The F1 score for the 1-, 3-, and 5-year models were 0.91, 0.88, and 0.85, respectively. The models exhibited superior performance in an external, independent dataset (1-year: AUC=0.889; 3-year: AUC=0.846; 5-year: AUC=0.821). Further, intensified endocrine therapy did not provide a significant overall survival benefit compared to initial or no endocrine therapy (P=0.600, HR: 1.46; 95% CI: 0.35-6.17). Propensity-score matching (PSM)-adjusted data showed that there was no statistically significant difference in the prognosis between ER-PR+HER2+ and ER-PR-HER2+ BC. Patients having the ER-PR+HER2- subtype had a slightly worse prognosis than those with the ER-PR-HER2- subtype. In conclusion, XGBoost models can be highly reproducible and effective in predicting survival in patients with sPR+ BC. Our findings revealed that patients with sPR-positive BC may not benefit from endocrine therapy. Patients with sPR+ BC may benefit from intensive adjuvant chemotherapy compared to endocrine therapy.

Citing Articles

Random survival forest predicts survival in patients with metastatic laryngeal and hypopharyngeal cancer and the prognostic benefits of surgery and radiotherapy.

Wang Y, Li C, Yang F, Gong M, Qu J, Ma R J Cancer. 2025; 16(2):603-621.

PMID: 39744488 PMC: 11685675. DOI: 10.7150/jca.103793.


Novel models by machine learning to predict the risk of cardiac disease-specific death in young patients with breast cancer.

Li Y, Li H, Ye X, Zhu Z, Qiu Y Discov Oncol. 2024; 15(1):809.

PMID: 39692943 PMC: 11655779. DOI: 10.1007/s12672-024-01676-9.


Prognostic prediction for inflammatory breast cancer patients using random survival forest modeling.

Jia Y, Li C, Feng C, Sun S, Cai Y, Yao P Transl Oncol. 2024; 52():102246.

PMID: 39675249 PMC: 11713504. DOI: 10.1016/j.tranon.2024.102246.


Machine learning predicts the risk of osteoporosis in patients with breast cancer and healthy women.

Zhao F, Li C, Wang W, Zhang Y, Yao P, Wei X J Cancer Res Clin Oncol. 2024; 150(2):102.

PMID: 38393381 PMC: 10891247. DOI: 10.1007/s00432-024-05622-8.

References
1.
Rhodes A, Jasani B . The oestrogen receptor-negative/progesterone receptor-positive breast tumour: a biological entity or a technical artefact?. J Clin Pathol. 2008; 62(1):95-6. DOI: 10.1136/jcp.2008.060723. View

2.
Horwitz K, Koseki Y, McGuire W . Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen. Endocrinology. 1978; 103(5):1742-51. DOI: 10.1210/endo-103-5-1742. View

3.
Kuerer H, Newman L, Smith T, Ames F, Hunt K, Dhingra K . Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999; 17(2):460-9. DOI: 10.1200/JCO.1999.17.2.460. View

4.
Keshgegian A, Cnaan A . Estrogen receptor-negative, progesterone receptor-positive breast carcinoma: poor clinical outcome. Arch Pathol Lab Med. 1996; 120(10):970-3. View

5.
Chan M, Chang M, Gonzalez R, Lategan B, Del Barco E, Vera-Badillo F . Outcomes of Estrogen Receptor Negative and Progesterone Receptor Positive Breast Cancer. PLoS One. 2015; 10(7):e0132449. PMC: 4498889. DOI: 10.1371/journal.pone.0132449. View